MIR184: A Potential Drug Target and Biomarker for Abnormal Clotting
MIR184: A Potential Drug Target and Biomarker for Abnormal Clotting
MIR184 (electronic dendrite-containing peptide with a thrombin-like activity and a unique molecular structure), also known as EDICT, is a protein that is expressed in various tissues and organs, including the brain, heart, kidneys, and intestines. Its unique molecular structure and thrombin-like activity make it an attractive drug target and a potential biomarker for several diseases.
MIR184 is a 21-kDa protein that is expressed in the brain, heart, kidneys, and intestines. It is characterized by a unique molecular structure that consists of a long amino acid sequence that is rich in electrostatic interactions and a short carboxylic acid tail. The carboxylic acid tail is important for the protein's stability and functions as a receptor for thrombin, a protein that plays a critical role in blood clotting.
MIR184's thrombin-like activity comes from its ability to interact with thrombin and other protein factors involved in blood clotting. This interaction causes MIR184 to participate in the clotting process by forming a covalent complex with thrombin and other clotting factors. This complex plays a key role in the formation of blood clots and can be a potential therapeutic target for diseases that are characterized by abnormal clotting.
One of the key advantages of MIR184 is its unique molecular structure, which allows it to be targeted by small molecules. This has led to a great deal of interest in using MIR184 as a drug or biomarker. Several studies have shown that MIR184 can be effectively targeted by small molecules, including inhibitors of thrombin and other protein factors involved in blood clotting.
In addition to its thrombin-like activity, MIR184 has also been shown to play a role in several other processes that are important for human health. For example, it has been shown to be involved in the regulation of inflammation, pain perception, and blood pressure.
The unique molecular structure of MIR184 also makes it an attractive target for drug development. MIR184 is a large protein with a total of 21 amino acids, which makes it relatively easy to produce and purify. This has led to the development of several potential MIR184-based drugs that are being investigated for their potential therapeutic applications.
One of the most promising potential applications for MIR184 is its potential as a drug target for diseases that are characterized by abnormal clotting. Several studies have shown that MIR184 can be effectively targeted by small molecules, including inhibitors of thrombin and other protein factors involved in blood clotting. This makes MIR184 an attractive candidate for the development of new treatments for disorders such as heart attack, stroke, and deep vein thrombosis.
In addition to its potential as a drug target, MIR184 has also been shown to be a potential biomarker for several diseases. For example, it has been shown to be involved in the regulation of inflammation, pain perception, and blood pressure. This makes MIR184 an attractive candidate for the development of new diagnostic tests for diseases such as cancer, neurodegenerative disorders, and inflammatory diseases.
In conclusion, MIR184 is a protein that is characterized by a unique molecular structure and a thrombin-like activity. Its potential as a drug target and biomarker makes it an attractive candidate for the development of new treatments and diagnostic tests for diseases characterized by abnormal clotting. Further research is needed to fully understand the role of MIR184 in human health and to develop effective treatments and diagnostic tests based on this protein.
Protein Name: MicroRNA 184
The "MIR184 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR184 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG | MIR2053 | MIR2054 | MIR205HG | MIR206 | MIR208A | MIR208B | MIR20A | MIR20B | MIR21 | MIR210 | MIR210HG | MIR211 | MIR2110 | MIR2113 | MIR2114 | MIR2115 | MIR2116 | MIR2117 | MIR212 | MIR214 | MIR215 | MIR216A | MIR216B | MIR217 | MIR217HG | MIR218-1 | MIR218-2 | MIR219A1 | MIR219A2 | MIR219B | MIR22 | MIR221 | MIR222 | MIR223 | MIR224 | MIR2276 | MIR2277 | MIR2278 | MIR22HG | MIR2355 | MIR2392 | MIR23A | MIR23AHG | MIR23B | MIR23C | MIR24-1 | MIR24-2
